医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FUJIFILM SonoSite, Inc. Announces President & CEO Kevin M. Goodwin Steps Down; Naohiro Fujitani Named President & CEO

2014年04月03日 PM02:38
このエントリーをはてなブックマークに追加


 

BOTHELL, Wash.

FUJIFILM SonoSite, Inc., the world leader and pioneering specialist in bedside and point-of-care ultrasound, announced that Kevin M. Goodwin has stepped down from his post as President and Chief Executive Officer, effective March 31, 2014, in order to pursue other opportunities. Naohiro Fujitani, President and Chief Executive Officer of FUJIFILM Medical Systems U.S.A., Inc., has been appointed to the position of President and Chief Executive Officer of FUJIFILM SonoSite, Inc., reporting to the Medical Systems Business Division, FUJIFILM Corporation. In addition to his new role with FUJIFILM SonoSite, Inc., Mr. Fujitani will also continue to serve as President and Chief Executive Officer of FUJIFILM Medical Systems U.S.A., Inc.

Mr. Fujitani has served as President and Chief Executive Officer of FUJIFILM Medical Systems U.S.A., Inc. since April 1, 2010. FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of medical image and information products and technologies for acquiring, processing, managing and storing diagnostic images and related data and is also a global leader in digital mammography. With nearly 40 years at Fujifilm, Mr. Fujitani is a knowledgeable and experienced leader who has spearheaded many business initiatives for Fujifilm.

Mr. Fujitani’s career with Fujifilm began at the company’s headquarters in Tokyo. Over the years, he has held positions of increasing responsibility, gaining experience in diverse functional areas such as sales, marketing, new product planning, system integration and software engineering management. Mr. Fujitani strongly intends to apply his experience and accomplishments – including the planning and introduction of a variety of innovative new products and businesses – in his new role at FUJIFILM SonoSite to achieve the goal of an expansion of the ultrasound medical systems business.

“Point of care ultrasound is rapidly expanding around the world and FUJIFILM SonoSite has been the leader in designing innovative products to meet the requirements of this rapidly developing global market. My goal is to use my extensive global business experience to support the expansion, and profitability of the company’s medical businesses and I look forward to working closely with the ultrasound team at FUJIFILM SonoSite,” said Mr. Fujitani.

About FUJIFILM SonoSite, Inc.

FUJIFILM SonoSite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan, brings continuous innovation and leading-edge products to a broad spectrum of industries, including electronic imaging, digital printing equipment, medical systems, life sciences, graphic arts, flat panel display materials, and office products, based on a vast portfolio of digital, optical, fine chemical and thin film coating technologies. The company was among the top 10 companies around the world granted U.S. patents in 2012, and in the year ended March 31, 2013, had global revenues of $26.7 billion*. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit www.fujifilmholdings.com.

* At an exchange rate of 83 yen to the dollar.

All product and company names herein may be trademarks of their registered owners.

CONTACT

Fujifilm
Diane Rainey, 914-798-8657
drainey@fujifilm.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent